Biosimilars: forging a pathway to patients
Biosimilars are one of the biggest talking points in the drug-making industry at present.
One only had to be at this month’s 2016 Annual European Congress of Rheumatology (EULAR) to witness how many drugs being developed in that therapy areas are biosimilars, and the amount of data and resources which companies are throwing at them.
Some of the biologic drugs which they supposedly replicate are massive sellers, the likes of Humira (adalimumab), currently sold by US pharma major AbbVie (NYSE: ABBV), and it is not just in rheumatology where several biosimilars are being developed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze